Umbilical cord plasma
1 paper5 findings
- 1 lab in 1 country
- Funder: National Institute on Aging
- 5 of 5 findings with company ties
- Human trial1
Outcomes
5Mitochondrial DNA copy number
no changein humans1
1 study
Mitochondrial DNA copy number
no changein humans1
Umbilical cord plasma has no effect on mitochondrial DNA copy number in humans.
“telomere length and mtDNA-CN were not significantly affected by the treatment.”
Human trialconcentrate1 ml10-weekn = 18
Aging cell2 Sep 2022
Telomere length
no changein humans1
1 study
Telomere length
no changein humans1
Umbilical cord plasma has no effect on telomere length in humans.
“while telomere length and mtDNA-CN were not significantly affected by the treatment.”
Human trialconcentrate1 ml10-weekn = 18
Aging cell2 Sep 2022
eGFR
upin humans1
1 study
eGFR
upin humans1
Umbilical cord plasma increases eGFR in humans (p = 0.0044).
“while estimated glomerular filtration rate (eGFR) was increased (p = 0.0044), indicating the treatment may improve biomarkers of kidney function.”
Human trialconcentrate1 ml10-weekn = 18
Aging cell2 Sep 2022
Creatinine
downin humans1
1 study
Creatinine
downin humans1
Umbilical cord plasma decreases creatinine in humans (p = 0.0039).
“For example, creatinine was significantly decreased (p = 0.0039), while estimated glomerular filtration rate (eGFR) was increased (p = 0.0044)”
Human trialconcentrate1 ml10-weekn = 18
Aging cell2 Sep 2022
GrimAge
downin humans1
1 study
GrimAge
downin humans1
Umbilical cord plasma decreases GrimAge in humans (-0.82 years, p = 0.0093).
“The treatment reduced DNA methylation-based GrimAge by an average of 0.82 years (p = 0.0093), suggests a reduction in morbidity and mortality risk.”
Human trialconcentrate1 ml10-weekn = 18
Aging cell2 Sep 2022